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Abstract
Objective: Cell-free fetal DNA is a source of fetal genetic material that can be used for non-invasive prenatal diagnosis.
Usually constituting less than 10% of the total cell free DNA in maternal plasma, the majority is maternal in origin.
Optimizing conditions for maximizing yield of cell-free fetal DNA will be crucial for effective implementation of testing. We
explore factors influencing yield of fetal DNA from maternal blood samples, including assessment of collection tubes
containing cell-stabilizing agents, storage temperature, interval to sample processing and DNA extraction method used.
Methods: Microfluidic digital PCR was performed to precisely quantify male (fetal) DNA, total DNA and long DNA fragments
(indicative of maternal cellular DNA). Real-time qPCR was used to assay for the presence of male SRY signal in samples.
Results: Total cell-free DNA quantity increased significantly with time in samples stored in K3EDTA tubes, but only minimally
in cell stabilizing tubes. This increase was solely due to the presence of additional long fragment DNA, with no change in
quantity of fetal or short DNA, resulting in a significant decrease in proportion of cell-free fetal DNA over time. Storage at
4uC did not prevent these changes.
Conclusion: When samples can be processed within eight hours of blood draw, K3EDTA tubes can be used. Prolonged
transfer times in K3EDTA tubes should be avoided as the proportion of fetal DNA present decreases significantly; in these
situations the use of cell stabilising tubes is preferable. The DNA extraction kit used may influence success rate of diagnostic
tests.
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Introduction
The presence of cell-free fetal DNA in the maternal circulation
offers an alternative source of fetal genetic material for prenatal
diagnosis [1]. It can be accessed without the risk of miscarriage
associated with the invasive procedures required to obtain
chorionic villi or amniocytes [2]. However, there are significant
technical challenges associated with this non-invasive approach to
prenatal diagnosis, since cell-free fetal DNA in early pregnancy
usually constitutes less than 10% of total circulating free DNA [3].
Current clinical applications of non-invasive prenatal diagnosis
(NIPD) are restricted to the identification of alleles present in the
fetus but not in the mother (either inherited from the father or
arising de novo), including sex determining genes [4], and RHD in
RhD negative mothers [5], as well as occasional diagnosis of
monogenic disorders [6], such as achondroplasia [7]. Recent
publications have described alternative approaches to extend the
range of monogenic disorders which may be amenable to prenatal
diagnosis based on cffDNA to include X-linked disorders, such as
haemophilia [8] as well as recessive ones, for example beta-
thalassaemia [9]. However, reports of clinical use of cffDNA for
clinical indications consistently describe failure to produce a
conclusive result in a small proportion of cases [10–12]. NIPD
based on cell-free fetal DNA in situations where both parents carry
a mutant allele for recessively-inherited monogenic disorders or for
the diagnosis of fetal aneuploidy is more challenging and may
depend on detection of small changes in relative proportions of
alleles using methods such as digital PCR [13,14] or next
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generation sequencing [15,16,17]. In this context, optimization of
the proportion of cell-free fetal DNA yield may become critical.
Studies in healthy volunteers have shown that total cell-free DNA
is increased in serum compared to plasma samples, and it increases
when blood is stored for 24 hours prior to centrifugation, the
effects presumed to be secondary to cell lysis over time [18].
Further studies using blood taken from pregnant women showed a
similar increase in total cell-free DNA over time, but using real-
time PCR demonstrated that the absolute quantity of cell-free fetal
DNA remained constant [19].
Genetic diagnostic services in the UK and Europe tend to be
regionalized, and current practice is that patient samples are
transported to the appropriate laboratory for analysis. Whilst
transport time is often less than a day, it can be considerably
longer, with some samples taking up to a week to arrive. Here, we
evaluate the factors that may maximize the yield of cell-free fetal
DNA, using digital PCR to accurately determine quantities of both
short (45–46 bp) and long (188–192 bp) amplicons in parallel
assays to count the number of short (predominantly fetal) and long
DNA (mainly maternal) fragments [20,21]. These data will inform
development of standards needed for implementation of this
technology into routine clinical practice.
Materials and Methods
Blood samples were collected from women attending the Fetal
Medicine Unit at University College Hospital NHS Foundation
Trust, London, for an invasive diagnostic test. Informed consent
was obtained prior to venepuncture and the study was approved
by the UCLH Ethics Committee A (ref 01/0095).
This study consists of four modules for testing different
conditions of storage prior to centrifugation. In a fifth module
we identified cases referred to our laboratory for fetal sex
determination because the mother was a carrier of a sex linked
disorder, where the test was inconclusive or had given a discordant
result. In these cases, where there was sufficient plasma stored we
used a different extraction kit before performing the PCR assay.
Module 1
DNA was extracted from 52 banked plasma samples [22]
processed at variable, but known, time intervals (range 2–
24 hours) following blood draw into K3EDTA collection tubes.
Plasma was stored at 280uC and samples were processed at one
time-point only in this module.
Module 2
To investigate the effect of varying the time interval between
blood draw and sample processing within individuals, three 10 ml
K3EDTA tubes of blood were collected from twelve pregnant
women. One tube was processed immediately (0 hour sample),
and the other two were stored at 4uC for four or 24 hours before
processing.
Module 3
To compare the effects of storage temperature on the
composition of the cell-free DNA, six 5 ml K3EDTA tubes of
blood were collected from ten pregnant women. Tube 1 was
processed immediately (0 hour sample). Tubes 2 and 3 were stored
for eight hours, one at room temperature and the second at 4uC.
Tubes 4 and 5 were kept for 24 hours at room temperature and 4uC
respectively. The 6th tube was stored at room temperature for
72 hours and then processed.
Module 4
To evaluate the use of the cell-stabilizing tubes (Cell-free DNA
BCTs, StreckTM) in comparison to K3EDTA tubes, blood from 20
individuals was drawn into three of each tube type. One K3EDTA
and one cell-stabilizing tube was processed immediately (0 hour
sample), one of each at 24 hours, and one of each at 72 hours. All
samples were stored at room temperature.
Module 5
To explore the possibility of reducing the number of
inconclusive results following NIPD for fetal sex determination
the Qiagen QIAamp Circulating Nucleic Acid (CNA) kit was used
to extract DNA from frozen plasma samples previously found to
be inconclusive when extracted using the QIAamp MinElute Virus
SpinTM (QV). Quantitative real time PCR using a Y-chromosome
specific assay (SRY) was carried out on each sample extracted in
parallel, using CCR5 as a control to confirm the presence of DNA
in the extracted sample.
For all modules plasma was separated from the blood cells by
centrifugation at 15006 g for ten minutes. The supernatant was
then transferred to fresh tubes, ensuring that the buffy coat
Table 1. Primer and probe sequences for the digital PCR assays.
Name Sequence
Short Duplex ZCCHC2-F TACCTGCGCTGTGGCCAATCGAATAAAACACACAGTACCGCGGCAGAG
ZCCHC2-46R CAGCACTGATGTAAGAGGTGCTG
TQ1 Probe CaO-ATTCGATTGGCCACAGCGCAGGTA-DQ
DYS_F_TQ2 AAGCTCAGTCATTTCCAGGTGTGCGAAAAGGGCCAATGTTGTATCCTTCTC
DYS_R 045 ACTAGAAAGGCCGAAGAAACACT
TQ2 Probe FAM-TCGCACACCTGGAAATGACTGAGCTT-DQ
Long Duplex ZCCHC2_F ACACACAGTACCGCGCAGAG
ZCCHC2_194R GGTCCAGGCATTGGATTAGGAT
ZCCHC2 PB CaO-CAGCACCTCTTACATCAGTGCTGTGG-DQ
DYS_F GGGCCAATGTTGTATCCTTCTC
DYS_188R CGCATGCAGGACAATAGTACCC
DYS14 PB FAM-TGTTTCTTCGGCCTTTCTAGTGGAGAGG-DQ
doi:10.1371/journal.pone.0025202.t001
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remained intact. The plasma was centrifuged at 160006g for ten
minutes to remove any remaining cells, transferred into two ml Lo-
Bind tubes (Eppendorf UK) and stored at 280uC until DNA
extraction.
DNA was extracted from 2 ml of plasma using the QIAamp
Circulating Nucleic Acid kit (Qiagen, UK) according to manu-
facturer’s instructions, and was eluted into a final volume of 50 ml
elution buffer.
Two duplex digital PCR assays were established for the
simultaneous amplification of either short or long sequences from
the Y chromosome (DYS14) and chromosome 18 (ZCCHC2).
Sequences of primers and probes are listed in Table 1. ZCCHC2
probes were labeled with Cal Fluor Orange and DYS14 probes
were labeled with FAM (Biosearch Technologies, Novato, CA).
The short (45–46 bp) assay was used to determine the total
quantity of DNA (maternal plus fetal) and the percentage of male
fetal DNA in a plasma DNA sample. The long (188–192) bp assay
was used to quantify the number and percentage of long DNA
molecules (predominantly maternal).
Digital PCR was carried out using 12.765 Digital ArrayTM chips
on the BioMarkTM System (Fluidigm, San Francisco). The chips
contain 12 panels with 765 chambers of 6 nL volume. Six samples
were analysed per chip, using one panel each for the short assay
duplex and one each for the long assay duplex. A final
concentration of 900 nM of each primer and 200 nM of each
probe was used with TaqMan Gene Expression Master Mix
(Applied Biosystems). The following PCR conditions were used:
50uC for two minutes, 95uC for ten minutes, then 45 cycles of 20 s
at 95uC and one minute annealing/extension at 60uC. Fluorescent
signals were read each cycle at 95uC.
The number of target molecules per panel was determined
using BioMark Digital PCR Analysis software. These counts were
then converted into copies per ml of plasma. Since the DYS14
assays detect 25–30 copies per Y chromosome, 30 copies per Y
chromosome was factored into converting the number of DYS14
targets to the number of Y targets. Paired comparisons of samples
from the same individuals were performed, thereby avoiding
distortion of results due to any variation in copy number of DYS14
between individuals.
Real-time quantitative PCR was carried out using the ABI7300
system (Applied Biosystems). An SRY Taqman assay (Applied
Biosystems) was used to detect male DNA, and a CCR5 Taqman
assay was used as a control to detect total DNA. 25 ml reactions were
prepared using 16 Taqman assay, 16 Taqman Universal PCR
Mastermix with no UNG (Applied Biosystems), and 5 ml of plasma
DNA. Six replicates were performed per sample for SRY detection
and three replicates for CCR5 per extract. Standard curves were
constructed for each gene using male genomic DNA (Promega).
Reporting criteria for fetal sexing at the North East Thames
Regional Molecular Genetics laboratory are summarized in
Table 2. Two separate maternal samples are analyzed; these can
be taken 1 week apart or at the same time after 9 weeks gestation.
Data analysis was performed using Sigma Stat 17.0 (SPSS Inc,
Chicago, IL). Significance was determined using a paired
Student’s t-test and P,0.05 was considered statistically significant.
Results
Module 1
Analysis of plasma samples, median gestational age 13+0 weeks
(Interquartile range (IQR) 12+4 to 13+4 weeks), processed at
known intervals following blood draw, showed that there is an
increase of both total DNA (Fig. 1A) and the percentage of long
DNA fragments (Fig. 1B) as time to process increases. There was
no significant change in the number of copies of male DNA
(Fig. 1C), and thus there is a gradual decrease in the proportion of
cell-free fetal DNA over time (Fig. 1D). For raw data for all
modules, see supporting information Table S1.
Table 2. Reporting criteria for fetal sexing.
No. of replicates of SRY,Ct45 Sex assignment
0 Female
1 Female if Ct.40;
2–4 Inconclusive
5,6 Male (standard deviation should be
no more than 1.5)
doi:10.1371/journal.pone.0025202.t002
Figure 1. Scatter plots showing (A) the total DNA copy number
per ml of plasma, (B) the percentage of long DNA, (C) the male
DNA copy number per ml of plasma, and (D) the percentage of
fetal DNA in plasma processed at different time points from
blood samples collected into EDTA tubes.
doi:10.1371/journal.pone.0025202.g001
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Module 2
No significant difference was seen between the total DNA or
long DNA copy number per ml of plasma at 0 and 4 hours
storage of blood at 4uC (Figs. 2A and 2B). Between 0 and
24 hours the median copy number of total or long DNA copy
number increases (Figs. 2A and 2B); however, no difference was
detected in the median copy numbers of fetal DNA at any time-
point (147 copies/ml (0 hours), 151 copies/ml (4 hours) and 196
copies/ml (24 hours); Fig. 2C). The percentage of the cell-free
fetal DNA remains the same after four hours, but decreases
between 0 and 24 hours (Fig. 2D). The median gestational age of
the fetuses from women studied in this module was 16+2 weeks
(interquartile range (IQR) 13+2 to 20+6 weeks). For summary
statistics for Module 2, and for subsequent modules, see
supporting information Table S2.
Module 3
Storage of blood at 4uC had no effect on the change over time
in level of total or long DNA copy number compared with storage
at room temperature (Figs. 3A and 3B). As in Module 2, no change
was observed in total copies of male DNA (Fig. 3C), resulting in a
decrease in the percentage of fetal DNA with time (Fig. 3D)
regardless of storage temperature. The median gestational age of
pregnancies tested in this module was 14+4 weeks (IQR 13+4 to
19+3 weeks).
Module 4
In this module samples from 20 pregnant women, nine of whom
were carrying male fetuses (median gestation 14+4 weeks, IQR
12+6 to 16+1 weeks) were examined. As previously noted in
plasma from blood collected into K3EDTA tubes, there was a
significant increase in total DNA copy number at both 24 hours
and 72 hours (Fig. 4A) with an associated decrease in proportion
of fetal DNA. However, when the blood was collected and stored
in cell-stabilizing tubes no change in the median quantity of total
DNA was observed at 24 hours, and there was only a slight
increase at 72 hours. The same absolute increase in copies was
seen with the K3EDTA tubes for long DNA (Fig. 4B), and again,
there was no increase in copy number with the cell-stabilizing
tubes at 24 hours. After 72 hours there was a small but clearly
significant increase in long copy number. There was a small but
significant decrease in the total quantity of male DNA in plasma
from samples stored in the cell-stabilizing tubes for 24 hours, but
this decrease was not seen in the samples stored for 72 hours, nor
would it be significant at the 99% confidence level. There was no
decrease in the quantity of male DNA in samples collected into
K3EDTA tubes at any time point (Fig. 4C). Consequently, whilst
the percentage of fetal DNA decreased significantly in samples
stored for 24 and 72 hours in K3EDTA tubes, there was no
significant difference in the percentage of cell-free fetal DNA in
samples stored for three days in cell-stabilizing tubes (Fig. 4D).
Figure 2. Samples processed at 0, 4, and 24 hours, stored at 46C. (A) Total DNA copy number per ml of plasma, (B) long DNA copy number
per ml of plasma; n = 12. (C) Male DNA copy number per ml of plasma, and (D) percentage of fetal DNA; n= 10. Mean for each set of data is
represented by a black bar, SEM is indicated, *indicates statistical significance.
doi:10.1371/journal.pone.0025202.g002
Prenatal Diagnosis: Factors Affecting cffDNA Yield
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25202
Module 5
DNA from fourteen pregnancies previously reported to be
inconclusive (including two pregnancies in which two samples
were taken a week apart and were both reported to be
inconclusive) were re-examined using real time PCR. Twelve
samples that were reported as inconclusive using the QV kit were
identified as male using DNA extracted using the CNA kit, and the
result obtained matched the birth outcome for nine of these (three
others have not been born yet) (table 3). Two samples were still
inconclusive, but a repeat of the test using the same sample may
have been enough to give a definite result.
Discussion
In this study we have shown that the increase in total cell free
DNA that occurs with increasing time from blood draw can largely
be prevented by taking blood into tubes which stabilize maternal
cells, thus allowing the proportion of cell-free fetal DNA to remain
more or less constant. Previous studies have all used quantitative
real-time PCR to quantify cell-free DNA in samples under
different conditions. Here, we apply digital PCR technology to
more accurately define the copy numbers of total DNA using very
short PCR assays, and use longer PCR amplicons (detecting
mainly maternal cell-free DNA) to determine the effect of various
pre-analytical factors on yield and composition of cell-free DNA.
Digital PCR has an advantage over quantitative PCR since it is
able to discriminate differences of less than twofold with great
accuracy. Since the technology is based on counting the template
molecules, there is no need to normalize to a reference, removing
any effect secondary to differences in efficiency in the PCR
reactions for two genes or between samples and a reference.
A short PCR assay for the ZCCHC2 gene on chromosome 18
was used to calculate the total copy number of cell-free DNA per
ml of plasma, whilst a long assay for the same gene was used to
determine the contribution of maternal cellular DNA to this
figure. The short DYS14 assay indicated the total quantity of fetal
DNA in the sample; only approximately 10% of the male DNA
was detected with the long assay for DYS14, confirming that fetal
DNA is predominantly apoptotic. The absolute copy number
increases after prolonged storage were the same as measuring with
the short PCR assays, indicating that newly released cellular DNA
is exclusively long and that no fragmentation of the cell-free DNA
occurs after the blood draw.
In the first series of experiments we analyzed individual blood
samples prepared at different time-points after blood draw and
demonstrated that there is a significant increase in total DNA, but
not cell-free fetal DNA as the time to process increases. These
samples were not only prepared at varying time intervals, they
were also taken at gestational ages across pregnancy. It is known
that cell-free fetal DNA levels increase with gestation [3] and that
maternal cell-free DNA can fluctuate on a daily basis [23]. To
eliminate any possible bias due to these, further experiments were
performed to assess the effect of time to process within women,
storage temperature, and cell-stabilizing tubes by taking multiple
Figure 3. Effects of time and storage temperature on cell-free DNA quantities. Plasma was processed at 0, 8, 24 and 72 hours, and stored at
room temperature (RT) or 4uC (4C). (A) Total DNA copy number per ml of plasma, (B) long DNA copy number per ml of plasma; n = 10. (C) Male DNA
copy number per ml of plasma, and (D) percentage of fetal DNA; n = 6. *indicates statistical significance.
doi:10.1371/journal.pone.0025202.g003
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samples from the same individual at the same time. The decrease
in proportion of cell-free fetal DNA was only prevented or reduced
by taking blood into tubes which stabilized maternal blood cells;
gestation and storage temperature had no effect. We have
demonstrated that this is not a result of degradation as the fetal
DNA levels remain constant; rather additional maternal DNA is
Figure 4. Samples were stored for 0, 24 or 72 hours in either K3EDTA tubes (E) or cell-stabilizing tubes (S). (A) Total DNA copy number
per ml of plasma, (B) long DNA copy number per ml of plasma; n = 20. (C) Male DNA copy number per ml of plasma, and (D) percentage of fetal DNA;
n = 9. *indicates statistical significance between samples in K3EDTA tubes; **indicates significance between the cell-stabilizing tubes.
doi:10.1371/journal.pone.0025202.g004
Table 3. Reduction in the number of inconclusive results obtained using the Qiagen CNA kit compared to the Qiagen QV kit.
Sample Gestation
No. of SRY
Positive (QV)
No. of SRY
Positive (CNA)
Average SRY
(CNA kit)
Average CCR5
(CNA kit)
Predicted Outcome
(CNA kit) Birth Outcome
1 8 3/6 5/6 35 25 Male Male
2 8+6 3/6 5/6 35 28 Male Male
3 17 3/6 6/6 34 30 Male Male
4 7+6 0/6 3/6 35 27 Inconclusive Male
5 8+4 0/6 6/6 37 27 Male Male
6 6+3 0/6 6/6 34 28 Male Male
7 9+1 3/6 6/6 35 28 Male Male
8 - 3/6 6/6 34 27 Male Male
9 7+2 4/6 6/6 35 25 Male Male
10 7 1/6 6/6 36 26 Male Male
11 11+ 0/6 6/6 35 28 Male -
12 9 2/6 6/6 35 28 Male -
13 7 0/6 1/6 - 27 Inconclusive -
13b 8 2/6 5/6 35 27 Male -
14 8+3 3/6 6/6 35 27 Male -
14b 9+3 3/6 6/6 36 27 Male -
doi:10.1371/journal.pone.0025202.t003
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released, and this DNA is predominantly (if not exclusively) long.
The percentage of long DNA (see supporting information in
Tables S1 and S2) can be used to determine the quality of a blood
plasma sample for further analysis. The lower the percentage of
long DNA, the better, since this indicates that there is less
contamination from maternal cells of the cell-free DNA. Previous
studies, using real time PCR suggested that cell-stabilizing tubes
could maintain the proportion of cell-free fetal DNA over long
periods [24]. However, using the more sensitive method of digital
PCR, we have shown that total cell-free DNA does increase
gradually over time, such that by 72 hours there was a small and
statistically very significant increase of long total, and thus
maternal, DNA. This observation may have implications for
clinical application and it would be interesting to see if this effect is
more pronounced with longer time intervals. Of note, the decrease
in proportion of cell-free fetal DNA in the small numbers of
EDTA samples posted to the laboratory did not appear to affect
SRY real-time PCR assay. However, if there is significant delay in
sample transfer this might affect performance, as suggested by
Finning et al where they attributed two of their three false RhD-
negative results of fetal RhD typing to postal delays of up to two
weeks [25]. Furthermore, it is likely that prompt preparation of
plasma or the use of collection tubes that prevent lysis of maternal
cells, will be required to optimize the proportion of cell-free fetal
DNA present when doing analyses based on sensitive counting of
copy numbers for the estimation of allelic ratios.
Our analyses may help to shed some light on a controversial
report by Dhallan, who reported increased recovery of fetal DNA
to a median of 25% from blood collected into formaldehyde-
containing tubes [26]. Whilst some groups were able to replicate
these findings [27], others found the differences in percentage of
fetal DNA to be insignificant [28,29]. It has been suggested that
these contradictory findings were caused by different processing
times between the untreated samples and the formaldehyde
stabilization samples that were being compared [30]. We have
shown that at four hours and eight hours following blood draw
there is no difference in proportion of fetal DNA in plasma from
cells stored in K3EDTA tubes or cell-stabilization tubes, but after
24 hours’ storage there are significant benefits to using cell-
stabilization tubes. Another discrepancy is that Dhallan detected a
much greater percentage of fetal DNA using a different technology
to others using real-time PCR. The percentage of cell-free fetal
DNA in the maternal plasma sample was determined by PCR
using serially-diluted plasma DNA and observing the highest serial
dilution in which the gene was detected. This limiting dilution
approach can be viewed as a precursor to microfluidic digital PCR
which, by using hundreds of replicates at a limiting dilution and
poisson statistics, enables a much more precise measurement of
DNA. The number of fetal copies detected by Dhallan but not the
proportion fits very well with our results. It is most probable that
the reported median 25% fetal DNA was actually a result of
under-detection of the total DNA control.
Finally we have shown that the use of the QIAamp Circulating
Nucleic AcidTM kit for cffDNA extraction has potential to decrease
the number of inconclusive results and increase accuracy by
avoiding false-negative results in maternal samples used to
determine fetal sex in pregnancies at risk of sex linked disorders.
This may be a reflection of the increased volume of plasma used
for the extraction using this kit (2 ml) as compared with the
Qiagen QIAamp MinElute Virus SpinTM (QV) which uses 400 ml.
However, due to the small volumes of plasma available for analysis
in this module we were unable to accurately evaluate the quantity
of cffDNA present. These results indicate the need for further
evaluation of DNA extraction kits to optimise the quantity of
cffDNA available for definitive diagnostic analysis.
In summary, we have shown that storage of blood samples at
4uC provides no advantage over storage at room temperature for
maximizing the proportion of cell-free fetal DNA in the plasma. If
possible, immediate centrifugation of a sample after blood draw is
preferable; when time to processing is going to be greater than
eight hours, the use of tubes containing material to stabilize cells is
useful to optimize cell-free fetal DNA levels. The DNA extraction
kit, and/or volume of plasma extracted may influence reliability of
testing in the clinical situation. Our findings may have significant
implications for implementing non-invasive prenatal diagnosis
based on cell-free fetal DNA into clinical practice.
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